Joele Frank is handling media for Alder BioPharmaceuticals, which is focused on the development and commercialization of migraine treatments, in its $2B sale to Denmark’s Lundbeck.
 |
The Danish company is offering $18 per-share for Alder, a 79 percent premium over its Sept. 13 closing price on the NASDAQ.
The owner of a portfolio of brain disease therapies will ante up another $2 per-share, if European regulators approve Alder’s next-generation eptinezumab migraine drug. The US Food & Drug Administration is on track to okay the treatment in February.
An estimated 135M people experience migraines annually. They are characterized by recurrent episodes of moderate to severe headaches accompanied by nausea, vomiting and sensitivity to sound and light.
CEO Deborah Dunsire called Alder an excellent strategic fit that leverages Lundbeck’s “specialized commercial expertise in delivering medicines for brain diseases.”
The transaction is expected to wrap up by yearend.
Joele Frank, Wilkinson Brimmer Katcher’s Andy Brimmer, Aura Reinhard and Tanner Kaufman represent Alder, while Stern Investor Relations’ Sarah McCabe works Wall Street for the Bothell, WA-based biopharmaceutical company.
Teneo is handling the initial public offering of CVC Capital Partners, one of Europe’s largest private equity firms with nearly $200B in assets under management.
Brunswick Group represents Endeavor Group Holdings as it agrees to go private via its acquisition by Silver Lake technology investment firm, which is handled by Edelman Smithfield.
Tod Donhauser, a nine-year veteran of Edelman, has joined H/Advisors Abernathy as managing director and head of its San Francisco office.
Intelligent Group Ltd, a Hong Kong-based financial PR firm, has priced its initial public offering of 1.9M shares at $4, which is the low end of the $4 to $5 range.
Kekst CNC represents Grant Thornton as it sells a majority stake in its US arm to New Mountain Capital, which relies on Goldin Solutions, in what is billed as the largest PE investment in the accounting and advisory sector.
Have a comment? Send it to 
No comments have been submitted for this story yet.